报价延迟最少15分钟:2025/07/21 06:36 EDT
盘前时段
|
||||
|
4.71 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.69
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.79/-2.82
|
|
企业价值
1.56B
|
| 资产负债 |
|
每股账面净值
9.49
|
| 现金流量 |
|
现金流量率
0.37
|
| 损益表 |
|
收益
2.70B
|
|
每股收益
34.03
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:36 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
